Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) EBITDA: 2016-2024

Historic EBITDA for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$44.6 million.

  • Mereo BioPharma Group's EBITDA fell 18.70% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year decrease of 18.80%. This contributed to the annual value of -$44.6 million for FY2024, which is 76.60% down from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's EBITDA is -$44.6 million, which was down 76.60% from -$25.3 million recorded in FY2023.
  • Mereo BioPharma Group's EBITDA's 5-year high stood at -$25.3 million during FY2023, with a 5-year trough of -$52.9 million in FY2022.
  • Moreover, its 3-year median value for EBITDA was -$44.6 million (2024), whereas its average is -$40.9 million.
  • Per our database at Business Quant, Mereo BioPharma Group's EBITDA slumped by 87.37% in 2022 and then skyrocketed by 52.22% in 2023.
  • Over the past 5 years, Mereo BioPharma Group's EBITDA (Yearly) stood at -$48.2 million in 2020, then surged by 41.50% to -$28.2 million in 2021, then plummeted by 87.37% to -$52.9 million in 2022, then soared by 52.22% to -$25.3 million in 2023, then crashed by 76.60% to -$44.6 million in 2024.